Lori J. Goldstein

24.7k total citations · 4 hit papers
164 papers, 10.9k citations indexed

About

Lori J. Goldstein is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lori J. Goldstein has authored 164 papers receiving a total of 10.9k indexed citations (citations by other indexed papers that have themselves been cited), including 124 papers in Oncology, 86 papers in Cancer Research and 33 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lori J. Goldstein's work include Breast Cancer Treatment Studies (79 papers), HER2/EGFR in Cancer Research (50 papers) and Cancer Treatment and Pharmacology (49 papers). Lori J. Goldstein is often cited by papers focused on Breast Cancer Treatment Studies (79 papers), HER2/EGFR in Cancer Research (50 papers) and Cancer Treatment and Pharmacology (49 papers). Lori J. Goldstein collaborates with scholars based in United States, Italy and United Kingdom. Lori J. Goldstein's co-authors include Mary Cianfrocca, Silvana Martino, Joseph A. Sparano, Nancy E. Davidson, Edith A. Perez, Donald A. Berry, George W. Sledge, I. Craig Henderson, Larry Norton and Michael M. Gottesman and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Lori J. Goldstein

160 papers receiving 10.5k citations

Hit Papers

Expression of Multidrug Resistance Gene in Human Cancers 1989 2026 2001 2013 1989 2014 2003 2006 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Expression of Multidrug Resistance Gene in Human Cancers
    1989 1.1k citations Lori J. Goldstein et al. profile →
  2. Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
    2014 953 citations Sylvia Adams, Robert J. Gray et al. Journal of Clinical Oncology profile →
  3. Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer
    2003 921 citations I. Craig Henderson, Donald A. Berry et al. Journal of Clinical Oncology profile →
  4. Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer
    2006 518 citations Donald A. Berry, Constance Cirrincione et al. profile →

Peers

Lori J. Goldstein
Peggy L. Porter United States
R. Kreienberg Germany
Joseph A. Sparano United States
Benjamin O. Anderson United States
Philippe L. Bédard Canada
Elżbieta Senkus Poland
William J. Gradishar United States
Terry Hyslop United States
Gong Tang United States
Gini F. Fleming United States
Peggy L. Porter United States
Lori J. Goldstein
Citations per year, relative to Lori J. Goldstein Lori J. Goldstein (= 1×) peers Peggy L. Porter

Countries citing papers authored by Lori J. Goldstein

Since Specialization
Citations

This map shows the geographic impact of Lori J. Goldstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lori J. Goldstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lori J. Goldstein more than expected).

Fields of papers citing papers by Lori J. Goldstein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lori J. Goldstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lori J. Goldstein. The network helps show where Lori J. Goldstein may publish in the future.

Co-authorship network of co-authors of Lori J. Goldstein

This figure shows the co-authorship network connecting the top 25 collaborators of Lori J. Goldstein. A scholar is included among the top collaborators of Lori J. Goldstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lori J. Goldstein. Lori J. Goldstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Handorf, Elizabeth A., Ramya Varadarajan, Jack O. Hensold, et al.. (2022). Prospective Comparison of Geriatric Assessment and Provider’s Assessment of Older Adults With Metastatic Breast Cancer in the Community. The Oncologist. 27(2). e133–e141. 1 indexed citations
3.
Bera, Kaustav, Paula Toro, Pingfu Fu, et al.. (2021). Collagen fiber orientation disorder from H&E images is prognostic for early stage breast cancer: clinical trial validation. npj Breast Cancer. 7(1). 104–104. 44 indexed citations
4.
O’Shaughnessy, Joyce, Javier Cortés, Chris Twelves, et al.. (2020). Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis. Scientific Reports. 10(1). 11203–11203. 8 indexed citations
5.
6.
Schott, Anne F., Lori J. Goldstein, Massimo Cristofanilli, et al.. (2017). Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2–Negative Metastatic Breast Cancer. Clinical Cancer Research. 23(18). 5358–5365. 181 indexed citations
7.
Adams, Sylvia, Robert J. Gray, Sandra Demaria, et al.. (2014). Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. Journal of Clinical Oncology. 32(27). 2959–2966. 953 indexed citations breakdown →
8.
Matro, Jennifer M., et al.. (2014). Bilateral Hypoglossal Nerve Palsy Due To Breast Cancer Skull Base Metastases. 10(5).
9.
10.
Sparano, Joseph A., Lori J. Goldstein, Barrett H. Childs, et al.. (2011). Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer. Clinical Cancer Research. 17(22). 7194–7203. 20 indexed citations
11.
Finn, Richard S., Carmelo Bengala, Nuhad K. Ibrahim, et al.. (2011). Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study. Clinical Cancer Research. 17(21). 6905–6913. 187 indexed citations
12.
Abramowitz, Matthew C., Tianyu Li, Monica Morrow, et al.. (2010). History of Smoking is Associated with Younger Age at Diagnosis of Breast Cancer. The Breast Journal. 16(4). 344–9. 9 indexed citations
13.
Sparano, Joseph A., Lori J. Goldstein, Barrett H. Childs, et al.. (2009). Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clinical Cancer Research. 15(24). 7693–7700. 21 indexed citations
14.
Berry, Donald A., Constance Cirrincione, I. Craig Henderson, et al.. (2006). Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer. Obstetrical & Gynecological Survey. 61(9). 584–585. 24 indexed citations
15.
Carlson, Robert W., Susan J. Moench, M. Elizabeth H. Hammond, et al.. (2006). HER2 Testing in Breast Cancer: NCCN Task Force Report and Recommendations. Journal of the National Comprehensive Cancer Network. 4(S3). S–1. 150 indexed citations
16.
Cianfrocca, Mary & Lori J. Goldstein. (2004). Prognostic and Predictive Factors in Early-Stage Breast Cancer. The Oncologist. 9(6). 606–616. 469 indexed citations
17.
Tedesco, Karen L., Ann D. Thor, Douglas H. Johnson, et al.. (2004). Docetaxel Combined With Trastuzumab Is an Active Regimen in HER-2 3+ Overexpressing and Fluorescent In Situ Hybridization–Positive Metastatic Breast Cancer: A Multi-Institutional Phase II Trial. Journal of Clinical Oncology. 22(6). 1071–1077. 83 indexed citations
18.
Cianfrocca, Mary & Lori J. Goldstein. (2001). Operable breast cancer. Current Treatment Options in Oncology. 2(2). 157–167. 3 indexed citations
19.
Goldstein, Lori J. & Robert F. Ozols. (1994). Anticancer drug resistance : advances in molecular and clinical research. Kluwer Academic eBooks. 27 indexed citations
20.
Goldstein, Lori J., et al.. (1992). Multidrug resistance in human cancer. Critical Reviews in Oncology/Hematology. 12(3). 243–253. 88 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peggy L. Porter Breakdown of academic impact, for papers by R. Kreienberg Breakdown of academic impact, for papers by Joseph A. Sparano Breakdown of academic impact, for papers by Benjamin O. Anderson Breakdown of academic impact, for papers by Philippe L. Bédard Breakdown of academic impact, for papers by Elżbieta Senkus Breakdown of academic impact, for papers by William J. Gradishar Breakdown of academic impact, for papers by Terry Hyslop Breakdown of academic impact, for papers by Gong Tang Breakdown of academic impact, for papers by Gini F. Fleming
Rankless by CCL
2026